Biomea Fusion Appoints Julianne Averill to its Board of Directors
Biomea Fusion (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, has appointed Julianne Averill to its Board of Directors, effective July 22, 2025. Averill, who will serve on the Audit Committee, brings over 20 years of experience in life sciences and digital health, currently serving as Managing Director at Danforth Advisors.
The appointment comes as Bihua Chen steps down after more than four years on the board. Averill's expertise includes capital markets, M&A, and operational scale, with involvement in transactions exceeding $10 billion in aggregate value. She holds both B.S. and M.S. degrees from California State University, along with CPA licensure and NACD Directorship Certification.
Biomea Fusion (Nasdaq: BMEA), un'azienda in fase clinica specializzata in farmaci per il diabete e l'obesità, ha nominato Julianne Averill nel suo Consiglio di Amministrazione, con effetto dal 22 luglio 2025. Averill, che farà parte del Comitato di Revisione, vanta oltre 20 anni di esperienza nelle scienze della vita e nella salute digitale, ricoprendo attualmente il ruolo di Managing Director presso Danforth Advisors.
La nomina avviene in seguito alla decisione di Bihua Chen di lasciare il consiglio dopo più di quattro anni. L’esperienza di Averill include mercati finanziari, fusioni e acquisizioni, e scalabilità operativa, con partecipazione a operazioni per un valore complessivo superiore a 10 miliardi di dollari. Ha conseguito sia la laurea triennale che magistrale presso la California State University, oltre a possedere la certificazione CPA e la certificazione NACD per amministratori.
Biomea Fusion (Nasdaq: BMEA), una compañía en etapa clínica dedicada a medicamentos para la diabetes y la obesidad, ha nombrado a Julianne Averill en su Junta Directiva, con efecto a partir del 22 de julio de 2025. Averill, quien formará parte del Comité de Auditoría, aporta más de 20 años de experiencia en ciencias de la vida y salud digital, desempeñándose actualmente como Managing Director en Danforth Advisors.
El nombramiento se produce tras la salida de Bihua Chen, quien dejó la junta después de más de cuatro años. La experiencia de Averill incluye mercados de capital, fusiones y adquisiciones, y escalamiento operativo, habiendo participado en transacciones por un valor agregado superior a 10 mil millones de dólares. Posee títulos de B.S. y M.S. de la California State University, además de la licencia CPA y la Certificación NACD para directores.
Biomea Fusion (나스닥: BMEA)는 임상 단계의 당뇨병 및 비만 치료제 개발 회사로, 2025년 7월 22일부터 줄리안느 애버릴을 이사회 멤버로 임명했습니다. 애버릴은 감사위원회에서 활동할 예정이며, 생명과학 및 디지털 헬스 분야에서 20년 이상의 경력을 보유하고 있으며, 현재 Danforth Advisors의 전무이사로 재직 중입니다.
이번 임명은 4년 이상 이사회에 있던 비화 첸이 물러난 후 이루어졌습니다. 애버릴의 전문 분야는 자본 시장, 인수합병(M&A), 운영 확장으로, 총 100억 달러가 넘는 거래에 참여한 경력이 있습니다. 그녀는 캘리포니아 주립대에서 학사 및 석사 학위를 받았으며, CPA 자격증과 NACD 이사 자격증을 보유하고 있습니다.
Biomea Fusion (Nasdaq : BMEA), une société en phase clinique spécialisée dans les médicaments pour le diabète et l'obésité, a nommé Julianne Averill à son conseil d'administration, à compter du 22 juillet 2025. Averill, qui siégera au comité d'audit, apporte plus de 20 ans d'expérience dans les sciences de la vie et la santé numérique, et occupe actuellement le poste de Managing Director chez Danforth Advisors.
Cette nomination intervient alors que Bihua Chen quitte le conseil après plus de quatre ans. L'expertise d'Averill couvre les marchés des capitaux, les fusions-acquisitions et la montée en puissance opérationnelle, avec une implication dans des transactions totalisant plus de 10 milliards de dollars. Elle est titulaire d'un B.S. et d'un M.S. de la California State University, ainsi que d'une licence CPA et d'une certification NACD en gouvernance d'entreprise.
Biomea Fusion (Nasdaq: BMEA), ein Unternehmen in der klinischen Entwicklungsphase für Diabetes- und Adipositasmedikamente, hat Julianne Averill mit Wirkung zum 22. Juli 2025 in seinen Vorstand berufen. Averill, die im Prüfungsausschuss tätig sein wird, bringt über 20 Jahre Erfahrung in den Bereichen Life Sciences und digitale Gesundheit mit und ist derzeit als Managing Director bei Danforth Advisors tätig.
Die Ernennung erfolgt, nachdem Bihua Chen nach mehr als vier Jahren im Vorstand zurückgetreten ist. Averills Expertise umfasst Kapitalmärkte, Fusionen und Übernahmen sowie operative Skalierung, mit Beteiligung an Transaktionen im Gesamtwert von über 10 Milliarden US-Dollar. Sie besitzt einen B.S. und M.S. Abschluss der California State University sowie eine CPA-Lizenz und die NACD-Direktoren-Zertifizierung.
- None.
- Loss of long-term board member Bihua Chen after 4+ years of service
SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced the appointment of Julianne Averill to its Board of Directors (the “Board”), effective July 22, 2025. Ms. Averill has also been appointed to serve as a member of the Audit Committee. She succeeds Bihua Chen, who has stepped down from the Board after more than four years of dedicated service.
“Julianne is an accomplished leader whose extensive financial, operational, and strategic expertise in the life sciences and digital health industries will be a tremendous asset to Biomea. Her proven track record in capital markets, governance, and healthcare innovation aligns with our mission to transform diabetes and obesity care. We look forward to Julianne’s contributions as we advance our programs and prepare for future growth,” said Mick Hitchcock, Interim Chief Executive Officer and member of the Board. “On behalf of the entire team and our Board, I would like to thank Bihua Chen for her many years of continued commitment to Biomea, her professional and expert guidance, and her ongoing support.”
Ms. Averill is a seasoned finance and strategy executive with over two decades of experience in high-growth life sciences and digital health companies across private, public, and global markets. She currently serves as Managing Director at Danforth Advisors, where she drives business growth on the West Coast and serves as interim Chief Financial Officer and strategic advisor to late-stage biopharma organizations. Her expertise spans capital markets, M&A, organizational design and operational scale, with direct involvement in transactions and strategic initiatives exceeding
Ms. Averill earned her B.S. in Business Administration and an M.S. in Accountancy, both from California State University. She is also a licensed CPA in California, is a Society of Human Resources Certified Professional, and holds the National Association of Corporate Directors Directorship Certification.
About Biomea Fusion
Biomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650, both being developed to significantly improve the lives of patients with diabetes, obesity, and metabolic diseases. We aim to cure.
Visit us at www.biomeafusion.com and follow us on LinkedIn, X and Facebook.
Contact:
Meichiel Jennifer Weiss
Sr. Director, Investor Relations and Corporate Development
IR@biomeafusion.com
FAQ
Who is the new Board Director at Biomea Fusion (BMEA)?
What experience does Julianne Averill bring to Biomea Fusion's board?
What is Julianne Averill's current role outside of Biomea Fusion?
Who did Julianne Averill replace on Biomea Fusion's board?
What are Julianne Averill's qualifications and certifications?
